Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methylprednisolone Sodium Succinate

FDA-approved product (injectable, injection), marketed as A-Methapred, Methylprednisolone, Methylprednisolone Sodium Succinate and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Methylprednisolone Sodium Succinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Anemia
  • Asthma
  • Atopic eczema
  • Bursitis
  • Crohn's disease
  • Dermatitis
  • Endocrine system disease
  • Frozen shoulder
  • Inflammation
  • Juvenile idiopathic arthritis
  • Leukemia
  • Lymphoma
  • Multiple sclerosis
  • Osteoarthritis
  • Pneumonia
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, weak (group i); Corticosteroids, combinations for treatment of acne; Glucocorticoids; Corticosteroids for systemic use, combinations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methylprednisolone Sodium Succinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methylprednisolone Sodium Succinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)

    NCT04593706 · start 2020-11-01

    Registered record
    Registry ID
    NCT04593706
    Conditions
    Keloid; Hypertrophic Scar; Scars; Scarring
    Interventions
    Betamethasone acetate + Betamethasone sodium phosphate; Dexamethasone sodium phosphate; Methylprednisolone acetate; Triamcinolone acetonide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-11-01
    Completion
    2021-10-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeloid; Hypertrophic Scar; Scars; Scarring
    InterventionBetamethasone acetate + Betamethasone sodium phosphate; Dexamethasone sodium phosphate; Methylprednisolone acetate; Triamcinolone acetonide
    PhaseNot applicable
    Registry statusUnknown

  • Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore

    NCT04871633 · start 2020-08-01

    Registered record
    Registry ID
    NCT04871633
    Conditions
    COVID-19
    Interventions
    Remdesivir; Conventional
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-08-01
    Completion
    2020-12-30
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionRemdesivir; Conventional
    PhaseNot applicable
    Registry statusCompleted

  • Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

    NCT04377503 · start 2020-05-01

    Registered record
    Registry ID
    NCT04377503
    Conditions
    Cytokine Release Syndrome; Covid-19
    Interventions
    Tocilizumab 180 MG/ML; Methylprednisolone Sodium Succinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-05-01
    Completion
    2020-11-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytokine Release Syndrome; Covid-19
    InterventionTocilizumab 180 MG/ML; Methylprednisolone Sodium Succinate
    PhasePhase 2
    Registry statusTerminated

  • Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan

    NCT04492501 · start 2020-04-01

    Registered record
    Registry ID
    NCT04492501
    Conditions
    Covid19; Cytokine Release Syndrome; Critical Illness; ARDS
    Interventions
    Therapeutic Plasma exchange; Convalescent Plasma; Tocilizumab; Remdesivir; Mesenchymal stem cell therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-04-01
    Completion
    2020-07-20
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Cytokine Release Syndrome; Critical Illness; ARDS
    InterventionTherapeutic Plasma exchange; Convalescent Plasma; Tocilizumab; Remdesivir +1 more
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of Different Intra-articular Injections Primary Gonarthrosis

    NCT05291793 · start 2020-04-01

    Registered record
    Registry ID
    NCT05291793
    Conditions
    Gonarthrosis; Primary
    Interventions
    Tenoxicam 20 Mg Powder for Solution for Injection Vial; Methylprednisolone; Saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-04-01
    Completion
    2021-08-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonarthrosis; Primary
    InterventionTenoxicam 20 Mg Powder for Solution for Injection Vial; Methylprednisolone; Saline
    PhaseNot applicable
    Registry statusCompleted

  • Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy

    NCT05199103 · start 2020-01-01

    Registered record
    Registry ID
    NCT05199103
    Conditions
    Graves Orbitopathy
    Interventions
    rabbit anti-thymocyte globulin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2023-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraves Orbitopathy
    Interventionrabbit anti-thymocyte globulin
    PhaseNot applicable
    Registry statusUnknown

  • Follow-up and Steroid Treatment Results in Intussusception

    NCT05640375 · start 2019-12-24

    Registered record
    Registry ID
    NCT05640375
    Conditions
    Intussusception
    Interventions
    Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-12-24
    Completion
    2023-12-24
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntussusception
    InterventionMethylprednisolone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pilocarpine After Combined Cataract/Trabectome Surgery

    NCT04005079 · start 2019-06-05

    Registered record
    Registry ID
    NCT04005079
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Pilocarpine; Ofloxacin; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2019-06-05
    Completion
    2021-01-21
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionPilocarpine; Ofloxacin; Prednisolone
    PhasePhase 3
    Registry statusWithdrawn

  • Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.

    NCT04622917 · start 2019-04-10

    Registered record
    Registry ID
    NCT04622917
    Conditions
    Rhinitis, Allergic, Seasonal; Hay Fever; Pollen Allergy; Allergic Rhinitis
    Interventions
    MethylPREDNISolone 40 Mg/mL Injectable Suspension; NaCl 9 MG/ML Injectable Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-04-10
    Completion
    2023-05-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Seasonal; Hay Fever; Pollen Allergy; Allergic Rhinitis
    InterventionMethylPREDNISolone 40 Mg/mL Injectable Suspension; NaCl 9 MG/ML Injectable Solution
    PhasePhase 4
    Registry statusCompleted

  • An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

    NCT03817853 · start 2019-02-26

    Registered record
    Registry ID
    NCT03817853
    Conditions
    Advanced Follicular Lymphoma
    Interventions
    Obinutuzumab; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone/Prednisolone/Methylprednisolone; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-02-26
    Completion
    2023-01-25
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Follicular Lymphoma
    InterventionObinutuzumab; Bendamustine; Cyclophosphamide; Doxorubicin +2 more
    PhasePhase 4
    Registry statusCompleted

  • A Study Investigating the Efficacy of GON Blocks.

    NCT04017741 · start 2018-02-14

    Registered record
    Registry ID
    NCT04017741
    Conditions
    Migraine; Chronic Migraine, Headache
    Interventions
    Combined Depo-Medrone and Lidocaine; Sodium Chloride 0.9% Inj
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-02-14
    Completion
    2020-01-23
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Chronic Migraine, Headache
    InterventionCombined Depo-Medrone and Lidocaine; Sodium Chloride 0.9% Inj
    PhasePhase 4
    Registry statusCompleted

  • A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

    NCT03110822 · start 2017-02-01

    Registered record
    Registry ID
    NCT03110822
    Conditions
    Multiple Myeloma
    Interventions
    Ruxolitinib Oral Tablet [Jakafi]; Lenalidomide; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2017-02-01
    Completion
    2027-02
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionRuxolitinib Oral Tablet [Jakafi]; Lenalidomide; Methylprednisolone
    PhasePhase 1
    Registry statusRecruiting

  • Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy

    NCT02647255 · start 2016-03

    Registered record
    Registry ID
    NCT02647255
    Conditions
    Glomerulonephritis, IGA; Kidney Diseases; Acute Renal Insufficiency; Rapidly Progressive Glomerulonephritis
    Interventions
    Plasma Exchange (PE); Methylprednisolone pulse
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2016-03
    Completion
    2020-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlomerulonephritis, IGA; Kidney Diseases; Acute Renal Insufficiency; Rapidly Progressive Glomerulonephritis
    InterventionPlasma Exchange (PE); Methylprednisolone pulse
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract

    NCT02425813 · start 2015-10

    Registered record
    Registry ID
    NCT02425813
    Conditions
    Acute Graft Versus Host Disease; Intestinal Graft Versus Host Disease
    Interventions
    Budesonide; Methylprednisolone Sodium Succinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-10
    Completion
    2016-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Graft Versus Host Disease; Intestinal Graft Versus Host Disease
    InterventionBudesonide; Methylprednisolone Sodium Succinate
    PhasePhase 2
    Registry statusWithdrawn

  • Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

    NCT02462252 · start 2015-10

    Registered record
    Registry ID
    NCT02462252
    Conditions
    Aplastic Anemia; Hypoplastic Myelodysplastic Syndrome
    Interventions
    BL-8040; horse anti-thymocyte globulin (hATG); Methylprednisolone; Cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-10
    Completion
    2020-11
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAplastic Anemia; Hypoplastic Myelodysplastic Syndrome
    InterventionBL-8040; horse anti-thymocyte globulin (hATG); Methylprednisolone; Cyclosporine
    PhasePhase 2
    Registry statusCompleted